CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project develops a microfluidic device called PeptiCHIP to streamline the identification of neoantigens for personalized cancer immunotherapy. By enabling rapid and accurate analysis of small tumor samples, it aims to enhance the effectiveness of immunotherapies tailored to individual patients.
Immunotherapeutic strategies have emerged as powerful tools to treat many types of cancers.
However, the majority of patients still fails to respond to immunotherapies as targetable tumour characteristics vary from patient to patient.
Thus, a greater degree of personalisation is required to fine-tune immunotherapies to the specific vulnerabilities of each patient’s tumour.
While therapies that target tumour-specific antigens (neoantigens) invoke a strong and specific anti-tumour immune response,…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
